Imugene Limited (IMU.AX)
ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.4200+0.0100 (+2.44%)
At close: 4:10PM AEDT
| Previous close | 0.4100 |
| Open | 0.4200 |
| Bid | 0.4200 x 102397000 |
| Ask | 0.4250 x 716752400 |
| Day's range | 0.4100 - 0.4250 |
| 52-week range | 0.0540 - 0.5150 |
| Volume | 6,987,731 |
| Avg. volume | 23,587,686 |
| Market cap | 2.303B |
| Beta (5Y monthly) | 2.21 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0040 |
| Earnings date | 29 Aug 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 0.47 |
- GlobeNewswire
Imugene and Celularity Announce an Exclusive Strategic Partnership to Develop a Novel Oncolytic Virus - Allogeneic CAR T-Cell Immunotherapy Combination for the Treatment of Solid Tumors
Collaboration will initially explore the therapeutic potential of a combination of Imugene’s CF33-CD19 oncolytic virus (onCARlytics) and Celularity’s CD19 targeting chimeric antigen receptor (CAR) placental-derived investigational T-cell therapy, CyCART-19Nonclinical in vitro and in vivo combination studies to commence in 2021Celularity’s off-the-shelf allogeneic CD19 therapy has shown sustained T-cell growth with continuous killing of tumor cells in vivo1Combining Imugene’s oncolytic virus tech
- Business Wire
Imugene Licenses Cd19 Oncolytic Virus From City of Hope to Turn Car T Therapy Against Solid Tumors
City of Hope and Imugene have entered into a licensing agreement for the patents covering a novel combination immunotherapy.
- Simply Wall St.
Announcing: Imugene (ASX:IMU) Stock Soared An Exciting 946% In The Last Five Years
Long term investing can be life changing when you buy and hold the truly great businesses. And highest quality...
© 2021 Verizon Media. All rights reserved.
